CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Arnab Ghosh, Sham Mailankody, Sergio A. Giralt, C. Ola Landgren, Eric L. Smith, Renier J. Brentjens

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies.

Original languageEnglish (US)
Pages (from-to)2056-2067
Number of pages12
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Sep 2 2018
Externally publishedYes


  • BCMA
  • CAR
  • chimeric antigen receptors
  • hematopoietic cell transplantation
  • immunotherapy
  • Multiple myeloma
  • TCR

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'CAR T cell therapy for multiple myeloma: where are we now and where are we headed?'. Together they form a unique fingerprint.

Cite this